James Michael O'brien Net Worth

The estimated Net Worth of James Michael O'brien is at least $217 Tysiąc dollars as of 27 October 2017. James brien owns over 22,866 units of Enzo Biochem stock worth over $56,669 and over the last 9 years James sold ENZ stock worth over $160,054.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James brien ENZ stock SEC Form 4 insiders trading

James has made over 2 trades of the Enzo Biochem stock since 2017, according to the Form 4 filled with the SEC. Most recently James exercised 22,866 units of ENZ stock worth $81,632 on 27 October 2017.

The largest trade James's ever made was exercising 22,866 units of Enzo Biochem stock on 27 October 2017 worth over $81,632. On average, James trades about 6,444 units every 23 days since 2016. As of 27 October 2017 James still owns at least 51,053 units of Enzo Biochem stock.

You can see the complete history of James brien stock trades at the bottom of the page.

What's James brien's mailing address?

James's mailing address filed with the SEC is C/O ENZO BIOCHEM INC., 527 MADISON AVE., NEW YORK, NY, 10022.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis... oraz Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of James brien stock trades at Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer